Cancer Communications

Cancer Communications

CANCER COMMUN
影响因子:24.9
是否综述期刊:
是否预警:不在预警名单内
是否OA:
出版国家/地区:PEOPLES R CHINA
出版社:BioMed Central
发刊时间:2015
发刊频率:
收录数据库:SCIE/Scopus收录/DOAJ开放期刊
ISSN:2523-3548

期刊介绍

Cancer Communications is an open access, peer-reviewed online journal that encompasses basic, clinical, and translational cancer research. The journal welcomes submissions concerning clinical trials, epidemiology, molecular and cellular biology, and genetics.
《癌症通讯》是一本开放获取、同行评审的在线期刊,涵盖基础、临床和转化癌症研究。该杂志欢迎有关临床试验,流行病学,分子和细胞生物学和遗传学的投稿。
年发文量 49
国人发稿量 40.48
国人发文占比 0.83%
自引率 -
平均录取率-
平均审稿周期 4 Weeks
版面费 -
偏重研究方向 Biochemistry, Genetics and Molecular Biology-Cancer Research
期刊官网 https://www.springer.com/journal/40880
投稿链接 https://www.editorialmanager.com/CHJC

期刊高被引文献

The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0349-9
Mucinous colorectal adenocarcinoma: clinical pathology and treatment options
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0361-0
The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-018-0346-4
Dual prognostic role of 2-oxoglutarate-dependent oxygenases in ten cancer types: implications for cell cycle regulation and cell adhesion maintenance
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0369-5
Immune contexture defined by single cell technology for prognosis prediction and immunotherapy guidance in cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0365-9
Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0356-x
PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0376-6
China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0383-7
National trend of gastric cancer mortality in China (2003–2015): a population-based study
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0372-x
Targeting mitochondria as an anticancer strategy
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0412-6
Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0354-z
Metabolic reprogramming and redox adaptation in sorafenib-resistant leukemia cells: detected by untargeted metabolomics and stable isotope tracing analysis
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0362-z
Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0351-2
Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score matching analysis
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0410-8
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0359-7
Pathological transition as the arising mechanism for drug resistance in lung cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0402-8
Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0385-5
Tumor mutational burden as a new biomarker for PD-1 antibody treatment in gastric cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0417-1
Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage I nasopharyngeal carcinoma
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0415-3
Moving beyond hydroxychloroquine: the novel lysosomal autophagy inhibitor ROC-325 shows significant potential in preclinical studies
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0418-0
Retrieved lymph nodes from different anatomic groups in gastric cancer: a proposed optimal number, comparison with other nodal classification strategies and its impact on prognosis
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0394-4
New frontiers in proton therapy: applications in cancers
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0407-3
Molecular analysis of cell-free DNA identifies distinct molecular features in patients with chemosensitive and chemorefractory small cell lung cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0363-y
Optimal sequencing of chemotherapy with chemoradiotherapy based on TNM stage classification and EBV DNA in locoregionally advanced nasopharyngeal carcinoma
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0398-0
Associations of PGK1 promoter hypomethylation and PGK1-mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan-cancer analysis
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0401-9
A novel role of LncRNA in regulating tumor metabolism and angiogenesis under hypoxia
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0348-x
Disrupting redox stabilizer: a novel therapeutic strategy for colorectal cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0355-y
Somatic mutations in renal cell carcinomas from Chinese patients revealed by targeted gene panel sequencing and their associations with prognosis and PD-L1 expression
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0382-8
Regulation of CD137 expression through K-Ras signaling in pancreatic cancer cells
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0386-4
Clinicopathological features and impact of adjuvant chemotherapy on the long-term survival of patients with multiple gastric cancers: a propensity score matching analysis
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0350-3
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0424-2
Clinical outcomes of angiosarcoma: a single institution experience
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0389-1
Microscopic tumor foci in axillary lymph nodes may reveal the recurrence dynamics of breast cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0381-9
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0375-7
Primary intrathoracic liposarcoma: a clinical analysis of 31 cases
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0358-8
Nuclear glycogenolysis modulates histone acetylation: a novel mechanism of epigenetic regulation in cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0420-6
Preferable background filtering for next-generation sequencing analysis in non-small cell lung cancer: pericarcinomatous tissues or peripheral blood lymphocytes?
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0378-4
Modelling the probability of erroneous negative lymph node staging in patients with colon cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0377-5
S-1 plus docetaxel: a safe and effective chemotherapy regimen for stage III gastric cancer
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0408-2
Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0403-7
Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0400-x
Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0409-1
Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0395-3
Is cancer-related death associated with circadian rhythm?
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0373-9
Radiation pneumonitis complicated by Pneumocystis carinii in patients with thoracic neoplasia: a clinical analysis of 7 cases
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0392-6
In pursuit of a flawless aphrodite: paving the way to scarless oncoplastic breast surgery
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0422-4
Correction to: Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0396-2
Skull bone tumor: a review of clinicopathological and neuroimaging characteristics of 426 cases at a single center
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0353-0
CD137 expression in cancer cells: regulation and significance
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0419-z
Correction to: Incidence, mortality, and temporal patterns of oropharyngeal cancer in China: a population-based study
来源期刊:Cancer CommunicationsDOI:10.1186/s40880-019-0352-1

质量指标占比

研究类文章占比 OA被引用占比 撤稿占比 出版后修正文章占比
61.22%82.8%--

相关指数

影响因子
影响因子
年发文量
自引率
Cite Score

预警情况

查看说明
时间 预警情况
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
*来源:中科院《 国际期刊预警名单》

JCR分区

WOS分区等级:Q1区
版本 按学科 分区
WOS期刊SCI分区
WOS期刊SCI分区
WOS期刊SCI分区是指SCI官方(Web of Science)为每个学科内的期刊按照IF数值排 序,将期刊按照四等分的方法划分的Q1-Q4等级,Q1代表质量最高,即常说的1区期刊。
(2024-2025年最新版)
ONCOLOGY
Q1

中科院分区

查看说明
版本 大类学科 小类学科 Top期刊 综述期刊
2025年3月最新升级版
医学1区
ONCOLOGY 肿瘤学
1区
2023年12月升级版
医学1区
ONCOLOGY 肿瘤学
2区
2022年12月旧的升级版
医学1区
ONCOLOGY 肿瘤学
1区